requirements
FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026
FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary
Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers
Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements